Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma
Reid W. Merryman(Harvard University), Caron A. Jacobson(Dana-Farber Cancer Institute), Justin Kline(University of Chicago), Robert Redd(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Oreofe O. Odejide(Dana-Farber Cancer Institute), Arnold S. Freedman(Otsuka (Japan)), Erin M. Parry(Broad Institute), Philippe Armand(Harvard University), Neha Mehta-Shah(Washington University in St. Louis), Inhye E. Ahn(Dana-Farber Cancer Institute), Iris Isufi(Yale University), Matthew S. Davids(Dana-Farber Cancer Institute), Matthew Mei(City of Hope), Nancy L. Bartlett(Washington University in St. Louis), Eric D. Jacobsen(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Jonathon B. Cohen(Emory University)
Cited by 1
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k